Braveheart Bio (NASDAQ:BRVE) Director David Charles Lubner Buys 55,555 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director David Charles Lubner purchased 55,555 shares of the business’s stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the completion of the acquisition, the director directly owned 55,555 shares of the company’s stock, valued at approximately $999,990. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Braveheart Bio Stock Up 0.7%

Shares of BRVE stock traded up $0.20 during trading hours on Friday, reaching $30.00. 565,846 shares of the company’s stock were exchanged. Braveheart Bio, Inc. has a fifty-two week low of $28.47 and a fifty-two week high of $32.00.

Get Braveheart Bio alerts:

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

See Also

• Five stocks we like better than Braveheart Bio
• Datadog’s Drop Says More About Expectations Than Earnings
• D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
• Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
• Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.